Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial
- 27 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (1) , 30-41
Abstract
Aims: Atrial fibrillation and flutter (AF) are common in patients with Type 2 diabetes and are associated with worse outcomes. Methods and results: Harmony Outcomes was a multi-centre, event-driven, double-blind, placebo-controlled trial comparing the effects of albiglutide, a glucagon-like peptide-1 receptor agonist, with placebo on a composite of major adverse cardiac events (MACEs; non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in 9463 patients aged >40 years with Type 2 diabetes and established cardiovascular disease. Herein, the cardiovascular effects of albiglutide in patients with and without AF, as well as the effects on AF events during follow-up, were analysed. Patients with a history of AF (8.9%) exhibited a higher event rate for the primary composite MACE endpoint during 1.6 years of follow-up {12.7 vs. 6.3 events/100 person-years, adjusted hazard ratio [aHR] 1.41 [95% confidence interval (CI) 1.14–1.74], P = 0.001}. Treatment with albiglutide reduced the occurrence of the primary endpoint irrespective of history of AF at baseline (history of AF: aHR 0.83 [0.58–1.19], no history of AF: aHR 0.77 [0.66–0.90]; Pinteraction = 0.71). During follow-up, 239 patients (2.5%) experienced an AF event. Overall, albiglutide was associated with numerically fewer AF events [108 vs. 131; hazard ratio 0.82 (0.63–1.06), P = 0.12], irrespective of baseline history of AF (Pinteraction = 0.92). Conclusion: In patients with Type 2 diabetes, treatment with albiglutide, compared with placebo, reduced the risk of cardiovascular events irrespective of history of AF. Further, albiglutide treatment did not increase AF adverse events but was associated with a trend to a lower rate of AF events during follow-up without reaching statistical significanceKeywords
Funding Information
- Max Kade Foundation
- GSK
This publication has 38 references indexed in Scilit:
- Glucagon-Like Peptide-1 Protects Against Atrial Fibrillation and Atrial Remodeling in Type 2 Diabetic MiceJACC: Basic To Translational Science, 2023
- Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonistsDiabetes & Metabolism, 2022
- Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2022
- Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trialDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2022
- Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fatJournal of Endocrinological Investigation, 2021
- Glucose-lowering drug use and new-onset atrial fibrillation in patients with diabetes mellitusDiabetologia, 2021
- GLP‐1 RA and atrial fibrillation in the cardiovascular outcome trialsDiabetes/Metabolism Research and Reviews, 2021
- Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristicsAmerican Heart Journal, 2018
- Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without DiabetesJACC, 2017
- Liraglutide causes large and rapid epicardial fat reductionObesity, 2017